Arbutus Biopharma Reports Q4 and Full-Year 2025 Financial Results and Corporate Update

Arbutus Biopharma Corporation (NASDAQ: ABUS) has released its financial results for the fourth quarter and full year ended December 31, 2025, and provided a comprehensive corporate update. The following are the key points and detailed highlights for investors and shareholders.

Key Financial Highlights

• Strong Cash Position: Arbutus ended 2025 with \$91.5 million in cash, cash equivalents, and marketable securities. This robust cash position is critical to sustaining operations, funding ongoing research and development, and providing financial flexibility for strategic initiatives.
• Significant Legal Settlement: The company, together with Genevant, secured a \$2.25 billion global settlement from Moderna for the infringement of its lipid nanoparticle (LNP) delivery technology. This settlement represents a transformative, potentially price-sensitive event and may have a material positive impact on Arbutus’s valuation and future strategic options. The details of the financial impact and allocation of this settlement have not yet been specified, and shareholders should closely monitor further disclosures.
• Net Loss Reduced: For the full year 2025, Arbutus reported a net loss of \$33.5 million, or \$0.17 per basic and diluted share, a significant improvement compared to the net loss of \$69.9 million, or \$0.38 per share, for 2024. This reduction reflects ongoing cost management and restructuring efforts.
• Restructuring Costs: The company incurred restructuring charges totaling \$12.9 million for 2025. All remaining restructuring-related payments are expected to be completed by the first quarter of 2026, which could further reduce operating expenses going forward.
• Share Count: As of December 31, 2025, 192.5 million common shares were issued and outstanding. Additionally, there were 14 million stock options and unvested restricted stock units outstanding.

Other Notable Updates and Potential Price Movers

• Clinical Pipeline Progress: The company reported two additional patients from its ongoing programs, though further clinical details or readouts are not specified in this filing. Investors should monitor upcoming announcements regarding clinical milestones, as these could be value drivers.
• Operating Metrics: Total revenue for 2025 was \$14.1 million, more than double the \$6.17 million reported in 2024, driven by licensing and collaboration activities. Interest income decreased to \$4.07 million from \$6.59 million in the prior year.
• Balance Sheet Strength: Total stockholders’ equity was \$76.6 million as of year-end 2025, versus \$97.4 million at the end of 2024. The company remains well-capitalized for its near-term development plans despite the decrease.
• Cash Flows: Net cash used in operating activities was significant due to ongoing development and restructuring, but investing activities generated \$15.6 million, and financing activities provided \$5.7 million. The issuance of common shares in prior periods contributed \$44.1 million in 2024; there were no such issuances in 2025.

Important Shareholder Information and Risks

• Emerging Growth Company Status: Arbutus is not classified as an emerging growth company, which means it is subject to full SEC reporting and compliance requirements.
• Forward-Looking Risks: The company cautions shareholders regarding the risks associated with ongoing litigation outcomes, regulatory approvals for product candidates, market shifts, and the sufficiency of its cash resources. Any adverse developments in these areas could materially impact share value.
• Potential Catalysts: Investors should closely watch for further announcements regarding the financial impact of the Moderna settlement, potential licensing deals, and clinical data readouts, as these are likely to be significant share price drivers.

Management Statement

The financial report is signed by Tuan Nguyen, Chief Financial Officer, on behalf of Arbutus Biopharma Corporation.

Exhibits and Additional Information

• Exhibit 99.1: The full press release dated March 23, 2026, is furnished as Exhibit 99.1, containing further details on the company’s performance and outlook.

Disclaimer: This article is a summary and interpretation of Arbutus Biopharma Corporation’s Form 8-K and accompanying press release for investor information purposes only. It does not constitute investment advice. Investors should review the full SEC filings and consult with their financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied herein.

View Arbutus Biopharma Corp Historical chart here